Buy Or Sell Opportunity • Jul 13
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 28% to CN¥43.66. The fair value is estimated to be CN¥54.67, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.0% over the last 3 years. Earnings per share has declined by 36%. Revenue is forecast to grow by 37% in 2 years. Earnings are forecast to grow by 95% in the next 2 years. Announcement • Jun 30
Xiangyu Medical Co.,Ltd to Report First Half, 2026 Results on Aug 29, 2026 Xiangyu Medical Co.,Ltd announced that they will report first half, 2026 results on Aug 29, 2026 Declared Dividend • Jun 15
Dividend reduced to CN¥0.18 Dividend of CN¥0.18 is 25% lower than last year. Ex-date: 17th June 2026 Payment date: 17th June 2026 Dividend yield will be 0.4%, which is lower than the industry average of 2.2%. Sustainability & Growth Dividend is covered by earnings (35% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 56 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 108% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Buy Or Sell Opportunity • May 05
Now 20% overvalued Over the last 90 days, the stock has fallen 13% to CN¥58.64. The fair value is estimated to be CN¥48.67, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 8.0% over the last 3 years. Earnings per share has declined by 36%. Revenue is forecast to grow by 23% in a year. Earnings are forecast to grow by 46% in the next year. Announcement • Apr 24
Xiangyu Medical Co.,Ltd, Annual General Meeting, May 18, 2026 Xiangyu Medical Co.,Ltd, Annual General Meeting, May 18, 2026, at 14:00 China Standard Time. Location: The Company's Meeting Room, Anyang, Henan China Reported Earnings • Apr 24
First quarter 2026 earnings released: EPS: CN¥0.16 (vs CN¥0.15 in 1Q 2025) First quarter 2026 results: EPS: CN¥0.16 (up from CN¥0.15 in 1Q 2025). Revenue: CN¥193.1m (up 3.8% from 1Q 2025). Net income: CN¥25.3m (up 10% from 1Q 2025). Profit margin: 13% (in line with 1Q 2025). Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. Announcement • Mar 30
Xiangyu Medical Co.,Ltd to Report Q1, 2026 Results on Apr 24, 2026 Xiangyu Medical Co.,Ltd announced that they will report Q1, 2026 results on Apr 24, 2026 Buy Or Sell Opportunity • Mar 24
Now 24% overvalued after recent price rise Over the last 90 days, the stock has risen 3.3% to CN¥55.59. The fair value is estimated to be CN¥44.91, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has declined by 28%. Revenue is forecast to grow by 39% in 2 years. Earnings are forecast to grow by 102% in the next 2 years. Reported Earnings • Mar 05
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: CN¥0.51 (down from CN¥0.66 in FY 2024). Revenue: CN¥767.7m (up 3.3% from FY 2024). Net income: CN¥78.7m (down 24% from FY 2024). Profit margin: 10% (down from 14% in FY 2024). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 5.4%. Earnings per share (EPS) also missed analyst estimates by 18%. Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings. New Risk • Jan 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (9.5% net profit margin). Announcement • Dec 26
Xiangyu Medical Co.,Ltd to Report Fiscal Year 2025 Results on Apr 24, 2026 Xiangyu Medical Co.,Ltd announced that they will report fiscal year 2025 results on Apr 24, 2026 Buy Or Sell Opportunity • Dec 19
Now 23% overvalued The stock has been flat over the last 90 days, currently trading at CN¥54.01. The fair value is estimated to be CN¥43.89, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has declined by 22%. Revenue is forecast to grow by 41% in 2 years. Earnings are forecast to grow by 122% in the next 2 years. Reported Earnings • Oct 31
Third quarter 2025 earnings released: EPS: CN¥0.058 (vs CN¥0.11 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.058 (down from CN¥0.11 in 3Q 2024). Revenue: CN¥178.0m (up 5.5% from 3Q 2024). Net income: CN¥8.59m (down 49% from 3Q 2024). Profit margin: 4.8% (down from 9.9% in 3Q 2024). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings. Announcement • Sep 30
Xiangyu Medical Co.,Ltd to Report Q3, 2025 Results on Oct 31, 2025 Xiangyu Medical Co.,Ltd announced that they will report Q3, 2025 results on Oct 31, 2025 Major Estimate Revision • Sep 29
Consensus EPS estimates fall by 27% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥870.5m to CN¥860.5m. EPS estimate also fell from CN¥1.18 per share to CN¥0.857 per share. Net income forecast to grow 88% next year vs 41% growth forecast for Medical Equipment industry in China. Consensus price target up from CN¥31.00 to CN¥58.00. Share price fell 5.1% to CN¥51.02 over the past week. Buy Or Sell Opportunity • Sep 19
Now 22% undervalued Over the last 90 days, the stock has risen 51% to CN¥53.51. The fair value is estimated to be CN¥68.47, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has declined by 14%. Revenue is forecast to grow by 52% in 2 years. Earnings are forecast to grow by 175% in the next 2 years. Buy Or Sell Opportunity • Jul 02
Now 25% undervalued Over the last 90 days, the stock has risen 10% to CN¥43.62. The fair value is estimated to be CN¥58.49, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has declined by 9.3%. Revenue is forecast to grow by 51% in 2 years. Earnings are forecast to grow by 165% in the next 2 years. Announcement • Jun 30
Xiangyu Medical Co.,Ltd to Report First Half, 2025 Results on Aug 29, 2025 Xiangyu Medical Co.,Ltd announced that they will report first half, 2025 results on Aug 29, 2025 Valuation Update With 7 Day Price Move • Jun 30
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to CN¥44.02, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 22x in the Medical Equipment industry in China. Total returns to shareholders of 32% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥50.70 per share. Buy Or Sell Opportunity • Jun 04
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 4.9% to CN¥39.45. The fair value is estimated to be CN¥49.59, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has declined by 9.3%. Revenue is forecast to grow by 51% in 2 years. Earnings are forecast to grow by 165% in the next 2 years. Reported Earnings • Apr 25
First quarter 2025 earnings released: EPS: CN¥0.15 (vs CN¥0.25 in 1Q 2024) First quarter 2025 results: EPS: CN¥0.15 (down from CN¥0.25 in 1Q 2024). Revenue: CN¥186.0m (up 10.0% from 1Q 2024). Net income: CN¥23.0m (down 41% from 1Q 2024). Profit margin: 12% (down from 23% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Announcement • Apr 25
Xiangyu Medical Co.,Ltd, Annual General Meeting, May 15, 2025 Xiangyu Medical Co.,Ltd, Annual General Meeting, May 15, 2025, at 14:00 China Standard Time. Location: The Company's Meeting Room, Anyang, Henan China Announcement • Mar 28
Xiangyu Medical Co.,Ltd to Report Q1, 2025 Results on Apr 25, 2025 Xiangyu Medical Co.,Ltd announced that they will report Q1, 2025 results on Apr 25, 2025 Valuation Update With 7 Day Price Move • Mar 26
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to CN¥36.51, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 19x in the Medical Equipment industry in China. Total returns to shareholders of 3.7% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥17.97 per share. Valuation Update With 7 Day Price Move • Mar 12
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥42.90, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 20x in the Medical Equipment industry in China. Total returns to shareholders of 23% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥18.09 per share. Reported Earnings • Feb 22
Full year 2024 earnings released: EPS: CN¥0.66 (vs CN¥1.44 in FY 2023) Full year 2024 results: EPS: CN¥0.66 (down from CN¥1.44 in FY 2023). Revenue: CN¥743.5m (flat on FY 2023). Net income: CN¥103.5m (down 54% from FY 2023). Profit margin: 14% (down from 31% in FY 2023). Revenue is forecast to grow 28% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 6% per year whereas the company’s share price has fallen by 4% per year. Valuation Update With 7 Day Price Move • Feb 21
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥38.98, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 20x in the Medical Equipment industry in China. Total loss to shareholders of 7.3% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥17.69 per share. New Risk • Feb 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (29% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.6% average weekly change). Profit margins are more than 30% lower than last year (17% net profit margin). Board Change • Jan 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Independent Director Zhong Ming Ye was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Dec 27
Xiangyu Medical Co.,Ltd to Report Fiscal Year 2024 Results on Apr 25, 2025 Xiangyu Medical Co.,Ltd announced that they will report fiscal year 2024 results on Apr 25, 2025 New Risk • Nov 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (29% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (10% average weekly change). Profit margins are more than 30% lower than last year (17% net profit margin). Announcement • Nov 11
Xiangyu Medical Co.,Ltd (SHSE:688626) announces an Equity Buyback for CNY 100 million worth of its shares. Xiangyu Medical Co.,Ltd (SHSE:688626) announces a share repurchase program. Under the program, the company will repurchase CNY 100 million worth of its shares. The shares will be purchased at a price not exceeding CNY 40 per share. The purpose of the program is to maintain the company's value and shareholders' interests. The program will be funded using company's own funds and/or special loans for share repurchase. The repurchase program is valid for 3 months. Valuation Update With 7 Day Price Move • Nov 11
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to CN¥35.72, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 20x in the Medical Equipment industry in China. Total loss to shareholders of 30% over the past three years. Reported Earnings • Oct 30
Third quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.46 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.11 (down from CN¥0.46 in 3Q 2023). Revenue: CN¥168.8m (down 19% from 3Q 2023). Net income: CN¥16.8m (down 77% from 3Q 2023). Profit margin: 9.9% (down from 35% in 3Q 2023). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to CN¥26.94, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 19x in the Medical Equipment industry in China. Total loss to shareholders of 46% over the past three years. New Risk • Sep 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (39% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.6% average weekly change). Announcement • Sep 30
Xiangyu Medical Co.,Ltd to Report Q3, 2024 Results on Oct 30, 2024 Xiangyu Medical Co.,Ltd announced that they will report Q3, 2024 results on Oct 30, 2024 Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥25.89, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 18x in the Medical Equipment industry in China. Total loss to shareholders of 54% over the past three years. Price Target Changed • Sep 07
Price target decreased by 16% to CN¥40.78 Down from CN¥48.78, the current price target is an average from 2 analysts. New target price is 74% above last closing price of CN¥23.42. Stock is down 40% over the past year. The company is forecast to post earnings per share of CN¥1.64 for next year compared to CN¥1.44 last year. Reported Earnings • Aug 30
Second quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.44 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.11 (down from CN¥0.44 in 2Q 2023). Revenue: CN¥168.8m (down 12% from 2Q 2023). Net income: CN¥17.6m (down 75% from 2Q 2023). Profit margin: 10% (down from 36% in 2Q 2023). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings. Announcement • Jun 29
Xiangyu Medical Co.,Ltd to Report First Half, 2024 Results on Aug 30, 2024 Xiangyu Medical Co.,Ltd announced that they will report first half, 2024 results on Aug 30, 2024 Announcement • Apr 19
Xiangyu Medical Co.,Ltd, Annual General Meeting, May 15, 2024 Xiangyu Medical Co.,Ltd, Annual General Meeting, May 15, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Anyang, Henan China Reported Earnings • Apr 18
First quarter 2024 earnings released: EPS: CN¥0.25 (vs CN¥0.24 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.25 (up from CN¥0.24 in 1Q 2023). Revenue: CN¥169.1m (up 18% from 1Q 2023). Net income: CN¥39.1m (up 3.3% from 1Q 2023). Profit margin: 23% (down from 26% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 18% per year, which means it is performing significantly worse than earnings. Announcement • Mar 29
Xiangyu Medical Co.,Ltd to Report Q1, 2024 Results on Apr 18, 2024 Xiangyu Medical Co.,Ltd announced that they will report Q1, 2024 results on Apr 18, 2024 Buy Or Sell Opportunity • Mar 22
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 9.9% to CN¥47.55. The fair value is estimated to be CN¥60.08, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.9% over the last 3 years. Earnings per share has declined by 11%. Revenue is forecast to grow by 50% in 2 years. Earnings are forecast to grow by 59% in the next 2 years. Valuation Update With 7 Day Price Move • Mar 13
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥48.00, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 21x in the Medical Equipment industry in China. Total returns to shareholders of 29% over the past year. Major Estimate Revision • Feb 29
Consensus EPS estimates fall by 15% The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate fell from CN¥2.00 to CN¥1.69 per share. Revenue forecast steady at CN¥902.0m. Net income forecast to grow 18% next year vs 33% growth forecast for Medical Equipment industry in China. Consensus price target down from CN¥63.00 to CN¥51.00. Share price was steady at CN¥42.38 over the past week. Reported Earnings • Feb 22
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2023 results: EPS: CN¥1.46 (up from CN¥0.79 in FY 2022). Revenue: CN¥744.8m (up 53% from FY 2022). Net income: CN¥229.6m (up 83% from FY 2022). Profit margin: 31% (up from 26% in FY 2022). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) missed analyst estimates by 11%. Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Valuation Update With 7 Day Price Move • Feb 05
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to CN¥35.29, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 17x in the Medical Equipment industry in China. Total loss to shareholders of 3.5% over the past year. Reported Earnings • Oct 26
Third quarter 2023 earnings released: EPS: CN¥0.46 (vs CN¥0.33 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.46 (up from CN¥0.33 in 3Q 2022). Revenue: CN¥207.1m (up 53% from 3Q 2022). Net income: CN¥71.5m (up 35% from 3Q 2022). Profit margin: 35% (down from 39% in 3Q 2022). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in China. New Risk • Oct 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (35% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (6.0% average weekly change). Valuation Update With 7 Day Price Move • Aug 13
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥39.65, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 22x in the Medical Equipment industry in China. Total returns to shareholders of 26% over the past year. Announcement • Aug 11
Xiangyu Medical Co.,Ltd (SHSE:688626) announces an Equity Buyback for CNY 160 million worth of its shares. Xiangyu Medical Co.,Ltd (SHSE:688626) announces a share repurchase program. Under the program, the company will repurchase CNY 160 million worth of its shares. The repurchase program is valid for 12 months. Reported Earnings • Aug 07
Second quarter 2023 earnings released: EPS: CN¥0.44 (vs CN¥0.19 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.44 (up from CN¥0.19 in 2Q 2022). Revenue: CN¥191.6m (up 41% from 2Q 2022). Net income: CN¥69.8m (up 129% from 2Q 2022). Profit margin: 36% (up from 23% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Announcement • Jun 28
Xiangyu Medical Co.,Ltd to Report First Half, 2023 Results on Aug 07, 2023 Xiangyu Medical Co.,Ltd announced that they will report first half, 2023 results on Aug 07, 2023 Reported Earnings • Apr 29
First quarter 2023 earnings released: EPS: CN¥0.24 (vs CN¥0.06 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.24 (up from CN¥0.06 in 1Q 2022). Revenue: CN¥143.2m (up 68% from 1Q 2022). Net income: CN¥37.8m (up 299% from 1Q 2022). Profit margin: 26% (up from 11% in 1Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 29% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Medical Equipment industry in China. Valuation Update With 7 Day Price Move • Mar 31
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥40.84, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 26x in the Medical Equipment industry in China. Total returns to shareholders of 9.0% over the past year. Reported Earnings • Feb 12
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: EPS: CN¥0.76 (down from CN¥1.35 in FY 2021). Revenue: CN¥488.5m (down 6.7% from FY 2021). Net income: CN¥121.2m (down 40% from FY 2021). Profit margin: 25% (down from 39% in FY 2021). The decrease in margin was primarily driven by higher expenses. Revenue missed analyst estimates by 19%. Earnings per share (EPS) also missed analyst estimates by 29%. Revenue is forecast to grow 32% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Reported Earnings • Oct 29
Third quarter 2022 earnings released: EPS: CN¥0.33 (vs CN¥0.28 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.33 (up from CN¥0.28 in 3Q 2021). Revenue: CN¥135.6m (up 1.1% from 3Q 2021). Net income: CN¥52.9m (up 17% from 3Q 2021). Profit margin: 39% (up from 34% in 3Q 2021). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Medical Equipment industry in China. Valuation Update With 7 Day Price Move • Oct 14
Investor sentiment improved over the past week After last week's 21% share price gain to CN¥38.19, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 23x in the Medical Equipment industry in China. Total loss to shareholders of 26% over the past year. Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improved over the past week After last week's 20% share price gain to CN¥31.55, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 23x in the Medical Equipment industry in China. Total loss to shareholders of 45% over the past year. Reported Earnings • Aug 20
Second quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.40 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.19 (down from CN¥0.40 in 2Q 2021). Revenue: CN¥135.8m (up 17% from 2Q 2021). Net income: CN¥30.5m (down 42% from 2Q 2021). Profit margin: 23% (down from 45% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 34%, compared to a 26% growth forecast for the Medical Equipment industry in China. Valuation Update With 7 Day Price Move • Jun 06
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥35.00, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 23x in the Medical Equipment industry in China. Total loss to shareholders of 62% over the past year. Reported Earnings • Apr 28
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: EPS: CN¥0.06 (down from CN¥0.21 in 1Q 2021). Revenue: CN¥85.1m (down 16% from 1Q 2021). Net income: CN¥9.48m (down 72% from 1Q 2021). Profit margin: 11% (down from 34% in 1Q 2021). The decrease in margin was primarily driven by lower revenue. Revenue missed analyst estimates by 8.2%. Earnings per share (EPS) also missed analyst estimates by 2.2%. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Chairman, General Manager & Technical Director Yongzheng He was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Announcement • Apr 12
Xiangyu Medical Co.,Ltd (SHSE:688626) announces an Equity Buyback for CNY 160 million worth of its shares. Xiangyu Medical Co.,Ltd (SHSE:688626) announces a share repurchase program. Under the program, the company will repurchase CNY 160 million worth of its shares. The program is valid for 12 months. Reported Earnings • Feb 24
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: EPS: CN¥1.32 (down from CN¥1.64 in FY 2020). Revenue: CN¥523.5m (up 5.6% from FY 2020). Net income: CN¥201.7m (up 2.8% from FY 2020). Profit margin: 39% (down from 40% in FY 2020). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 8.2%. Earnings per share (EPS) also missed analyst estimates by 4.3%. Over the next year, revenue is forecast to grow 38%, compared to a 24% growth forecast for the industry in China. Valuation Update With 7 Day Price Move • Jan 21
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥49.34, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 28x in the Medical Equipment industry in China. Valuation Update With 7 Day Price Move • Jan 06
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥64.12, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 30x in the Medical Equipment industry in China. Board Change • Oct 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Chairman, General Manager & Technical Director Yongzheng He was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Valuation Update With 7 Day Price Move • Jul 28
Investor sentiment deteriorated over the past week After last week's 15% share price decline to CN¥66.40, the stock trades at a trailing P/E ratio of 41.1x. Average trailing P/E is 36x in the Medical Equipment industry in China. Valuation Update With 7 Day Price Move • Jul 06
Investor sentiment deteriorated over the past week After last week's 25% share price decline to CN¥85.00, the stock trades at a trailing P/E ratio of 52.6x. Average trailing P/E is 41x in the Medical Equipment industry in China. Valuation Update With 7 Day Price Move • Jun 19
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥96.30, the stock trades at a trailing P/E ratio of 59.6x. Average trailing P/E is 39x in the Medical Equipment industry in China. Valuation Update With 7 Day Price Move • May 31
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥99.00, the stock trades at a trailing P/E ratio of 61.3x. Average trailing P/E is 40x in the Medical Equipment industry in China. Valuation Update With 7 Day Price Move • May 14
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥84.33, the stock trades at a trailing P/E ratio of 52.2x. Average trailing P/E is 38x in the Medical Equipment industry in China.